Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

ndicates the improvement in DAS-28 compared to placebo was statistically significant in the 800 mg dose group at 12 weeks and at all subsequent assessments, and in the 1600 mg dose group at 16 weeks and at all subsequent assessments. At 24 weeks, ACR 20, 50 and 70 response rates in the 800 mg dose group were 65 percent, 26 percent and 0 percent, respectively. ACR 20, 50 and 70 response rates in the 1600 mg dose group were 61 percent, 13 percent and 4 percent, respectively. ACR 20, 50 and 70 response rates at 24 weeks in the placebo group were 33 percent, 9 percent and 2 percent, respectively.

TRU-015 administered as a single dose was generally well tolerated, and only one subject in the 400 mg group experienced a grade 3 adverse event on the day of infusion.

"We are pleased that the positive results of this study confirm the activity seen in our prior study and demonstrate that TRU-015 can meaningfully improve disease activity in patients with RA," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "We are working with our partner to define the most effective development strategy for TRU-015 in RA that minimizes time-to-market while maximizing our competitive differentiation. We currently believe this will include additional clinical study before commencement of a Phase III trial."

Conference Call Details

Trubion will host a conference call and webcast to discuss its preliminary analysis of the Phase IIb results with TRU-015 for RA. The call will be held today at 1:30 p.m. Pacific Time, 4:30 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling (800) 289-0494 or (913) 981-5520. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling (888) 203-1112 or (719) 457-0820, and entering 5763754. The telephone replay
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... Partnership to Fight Chronic Disease (PFCD) released a public opinion poll ... new study analyzing the impact of increased cost sharing on patient ... to educate policy makers and the public on the costs of ... how the Iowa healthcare exchange could be ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Data from experimental work on the use,of ... this week at the,International Society for Heart and ... donors after cardiac death,(DCD), also known as non-heart-beating ... shortage of suitable donor organs for lung, and,possibly ...
... Institute,s NABTT ... Consortium -, ... expansion of the clinical program for the company,s lead,product candidate, BSI-201, ... first poly ADP-ribose polymerase,(PARP) inhibitor in BiPar,s DNA repair portfolio, crosses ...
Cached Medicine Technology:Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation 2Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation 3BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... Dallas, TX (PRWEB) December 26, 2014 The ... covered in this report. In 2013, GlobalData’s forecast estimates that ... the largest CRC market due to the high incidence of ... compared with the 5EU, Japan, and China. Increased sales of ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... have slowed to less than half the growth rate from ... in the health care system continue to fuel underlying health ... , , Prepared by PricewaterhouseCoopers ... Factors Fueling Rising Healthcare Costs 2008" examines the causes of ...
... The Michigan Quality Council,(MQC) announces that the Detroit Athletic ... The Michigan Quality Leadership Award is ... It is awarded after a,rigorous review by a team of ... report for final evaluation to an independent panel of,judges. , ...
... definitively that blood stem cells are made during mid-gestational embryonic ... of blood vessels. , While the anatomic location in ... documented, the cell type from which they spring was less ... issue of the journal Cell Stem Cell , puts ...
... Dec. 3 BeaconEquity.com announces the availability of Trade Alerts on stocks making ... all of the daily trading notes for free by visiting: http://www.BeaconEquity.com/m ... Inc. (NYSE: SPC ), Williams-Sonoma Inc. (NYSE: WSM ), ... WXS ), Morgans Hotel Group Co. (Nasdaq: MHGC ) and ...
... U.S. Environmental Protection Agency,s process of generating risk assessments ... harmful chemicals found in the environment in order to ... challenges, and as a decision-making tool it is often ... the information needs of officials, says a new report ...
... CEO of Americans United for Life released the following statement ... make funding embryo destructive stem cell research a priority. , ... of the economy, to squander taxpayer resources on research that ... that in fact runs counter to the latest stem cell ...
Cached Medicine News:Health News:New Report Shows Slower Premium Growth, But Increasing Pressure to Address Waste in Health Care System 2Health News:New Report Shows Slower Premium Growth, But Increasing Pressure to Address Waste in Health Care System 3Health News:MICHIGAN QUALITY COUNCIL (MQC) NAMES The Detroit Athletic Club 2008 STATE QUALITY AWARD RECIPIENT 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 3Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:EPA's risk assessment process bogged down by unprecedented challenges; 2Health News:EPA's risk assessment process bogged down by unprecedented challenges; 3Health News:EPA's risk assessment process bogged down by unprecedented challenges; 4
... your practice with the advantages of the IPL ... of leg veins and other deeper vascular lesions. ... As a stand alone device or as an ... DL treats a range of conditions including: ...
Disposable. Sterile Suction Tubing....
... say the most efficient,aspiration is ... movement of the,cannula tip. Rigorous ... ARC-H II Reciprocating Cannula,assures that ... is,restricted to a longitudinal axis ...
Inquire...
Medicine Products: